ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1367

Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry

ŽIga Rotar1 and Matija Tomsic2, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), anti-TNF therapy, Psoriatic arthritis, rheumatoid arthritis (RA) and tuberculosis

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation of treatment, adds to the overall cost of treatment, and carries risk of adverse events in its own right. Since 2002 our national guidelines require following a two-step screening algorithm prior to the initiation of the first TNFi. The first step includes tuberculin skin test (TST), and a chest X-ray (CXR). If TST < 5 mm, and the radiologist finds no changes consistent with TB on CXR TNFi is prescribed. If any test is abnormal, the patient is evaluated by a pulmonologist who usually orders QuantiFERON TB Gold IT (QF) and decides whether TB CP (rifampicin/isoniazid 600/300 mg qd for 3 months) is required prior to TNFi treatment.

In February 2012 we showed that in a setting with low background annual TB incidence rate (IR; e.g. 8.4 per 105) following of this algorithm resulted in TB IR of 0.11 (95% CI 0.01–0.38), and 0.16 (95% CI 0.02–0.58) per 100 person years (PY) overall, and in rheumatoid arthritis (RA) patients, respectively. The costly QF and CP were required in 13.9%, and 5.2% of patients, respectively. Our aim was to revaluate the performance of this algorithm.

Methods: We cross-linked the data from the mandatory national registry of patients with rheumatic diseases treated with biologics and national TB registry to identify cases of TB in patients who were ever treated with TNFi.

Results: 1203 patients were treated with at least one TNFi for 3146.5 PY (Table 1). Flow of patients through the screening algorithm and case patient characteristics are depicted in Figure 1. QF was performed in 214/1174 (18.2%). 88/1203 (7%) patients received CP. Four cases of TB were identified; hence the incidence rates were 0.13 (95%CI 0.03–3.2), and 0.22 (95% CI 0.06–0.57) per 100 PY overall, and in RA patients, respectively. Cases of TB were only observed among RA patients. The TB IR for certolizumab vs. other TNFi prescribed for RA was 2.1 (95% CI 2.56–7.40) vs. 0.12 (95% CI 0.01–0.43) per 100 PY (p=0.016 Fisher’s exact test). The first two received appropriate CP (adherence was good, isolated M. tuberculosis strains were susceptible to CP) prior to TNFi; screening was concluded after 1st, and 2nd step for the third and fourth patient, respectively. Interestingly, the third case was screened for TB again before switching to rituximab. At repeated screening two months prior to TB diagnosis the TST was 10 mm, CXR –. and QF–.

Conclusion: At follow-up our two-step algorithm is still performing well. Further vigilance is warranted, especially in RA patients and those treated with CPZ.

Table 1.

 

Rheumatoid arthritis

Ankylosing spondylitis

Psoriatic arthritis

N (%)

701 (58.3)

331 (27.5)

171 (14.2)

% female

82

34

41

Age at screening (SD)

54.9 (11.6)

45.8 (11.6)

49 (11.2)

% Glucocorticoids at screening

47.0

/

/

% ever glucocorticoids

66.2

/

/

TNFi exposure years

1792.5

950.6

403.4

% Adalimumab (ADA)

44.4

36.9

44.4

% Certolizumab (CZP)

5.3

0.0

0.3

% Etanercept (ETA)

37.4

31.1

27.2

% Golimumab (GOL)

2.3

7.1

10.9

% Infliximab (IFX)

10.7

24.9

17.2

Figure 1

 


Disclosure:

Rotar,
None;

M. Tomsic,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-a-two-step-latent-tuberculosis-screening-algorithm-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-or-ankylosing-spondylitis-prior-to-treatment-with-tumor-necrosis-alpha-inhi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences